FREMONT, Calif., May 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "PF-04523655 (REDD14NP), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation," at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place from May 3-7, 2009, in Fort Lauderdale, Florida. PF-04523655 is currently being studied by partners Pfizer and Quark in patients with diabetic macular edema (DME) and age-related macular degeneration (AMD).
The study presented at ARVO was performed in collaboration with Dr. Jayakrishna Ambati at the Department of Ophthalmology and Visual Sciences, University of Kentucky College of Medicine, Lexington, KY. The objective of the study was to determine whether PF-04523655, a synthetic chemically modified 19-bp siRNA, enters cells in the retina leading to downregulation of its target gene while avoiding activation of Toll Like Receptor 3 (TLR3). Previous studies from Dr. Ambati's laboratory have shown that unmodified 21-mer siRNA molecules exhibit antiangiogenic effects by inadvertently activating TLR3 rather than down-regulating expression of their target genes. Results obtained in vivo and in vitro indicated that PF-04523655 does enter cells in the retina and elicits its pharmacologic effect via target gene knock-down without activating TLR3.
Daniel Zurr, Ph.D., President and Chief Executive Officer, said, "We believe that the results presented at ARVO continue to substantiate our leadership in siRNA therapeutics, in particular Quark's ability to develop highly specific siRNA products and advance them through the clinic toward commercialization. Quark's ability to establish col
'/>"/>
SOURCE Quark Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference2.
FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry3.
Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 20084.
Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting5.
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes6.
China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results7.
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML8.
XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 20079.
Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results10.
Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences11.
Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer